Actelion Ltd. (ALIOF.PK) Sales Rise Ahead of Anticipated Drug Approval
10/17/2013 6:58:32 AM
Actelion, Europe's largest biotech company, confirmed its full-year outlook on Thursday ahead of a widely anticipated approval of its big drug hope Opsumit by U.S. health regulators later this week. Nine month sales of its main product Tracleer, a treatment for pulmonary arterial hypertension (PAH), rose 3 percent to 1.138 billion Swiss francs ($1.24 billion). Net profit was 105 million francs in the third quarter, beating analysts' forecasts of 88.5 million.
Help employers find you! Check out all the jobs and post your resume.
comments powered by